Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial

JAMA

Volumn 286, Issue 23, 2001, Pages 2956-2967

  Casale, Thomas B ^a   Condemi, John ^b   LaForce, Craig ^c   Nayak, Anjuli ^d   Rowe, Michael ^e   Watrous, Marc ^f   McAlary, Margaret ^g   Fowler Taylor, Angel ^g   Racine, Amy ^g   Gupta, Niroo ^g   Fick, Robert ^f   Della Cioppa, Giovanni ^h  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c North Carolina Clinical Research Inc   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Michigan Resp Hlth/Res Institute   (United States)

^f GENENTECH INC   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALGORITHM; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SELF EVALUATION; SKIN TOXICITY;

EID: 0035915364     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.23.2956     Document Type: Article

References (45)

1. Allergic rhinitis: Offering relief this season
2. Pathophysiology and treatment of seasonal allergic rhinitis
3. Subjective and objective assessments in patients with seasonal allergic rhinitis
4. Prevalence of allergic rhinitis and atopic dermatitis among children in four regions of Finland
5. Changing prevalence of allergic rhinitis and asthma
6. The prevalence of allergic rhinosinusitis: A review
7. Epidemiology of seasonal and perennial rhinitis
8. A cost of illness study of allergic rhinitis in the United States
9. Chronic sinusitis: Relationship of computed tomographic findings to allergy, asthma, and eosinophilia
10. Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies
11. Overview of comorbid associations of allergic rhinitis
12. Quality of life, rhinitic symptoms
13. Evaluation and management of allergic rhinitis
14. The costs of allergic rhinitis
15. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses
16. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis
17. Rhinitis and inhalant allergens
18. Pharmacological treatment options for allergic rhinitis and asthma
19. First line treatment of seasonal (ragweed) rhinoconjunctivitis
20. Symptom control in patients with hay fever in UK general practice
21. Humanization of an antibody directed against IgE
22. Mechanisms of hypersensitivity
23. Distribution and incidence of North American pollen aeroallergens
24. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
25. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
26. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
27. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
28. On the combination of independent two-sample tests of Wilcoxon
29. Interpretation of rhinoconjunctivitis quality of life questionnaire data
30. Multiple doses of a recombinant humanized monoclonal anti-IgE antibody are safely tolerated and decrease free serum IgE to undetectable levels
31. Pharmacokinetics and clearance mechanisms of anti-IgE
32. Safety of readministration of rhuMab-E25 in seasonal allergic rhinitis (SAR)
33. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
34. The cellular response of the human allergic mucosa to natural allergen exposure
35. Functional analysis of a T cell line specific II, for anti-idiotypic antibodies to a Schistosoma mansoni protective epitope. II
36. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis
37. Accelerated elimination of N. brasiliensis from the small intestine after auto-anti-IgE induction
38. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice
39. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray
40. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis
41. Do inhaled corticosteroids stunt the growth of children?
42. Ideal pharmacotherapy for allergic rhinitis
43. Treatment of allergic asthma with monoclonal anti-IgE antibody
44. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics